Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose

Neuroscience Bulletin

Volumn 28, Issue 5, 2012, Pages 561-566

  Sun, Xiao Jing ^a   Zhao, Lei ^a   Zhao, Na ^a   Pan, Xiao Li ^a   Fei, Guo Qiang ^a   Jin, Li Rong ^a   Zhong, Chun Jiu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

amyloid; Alzheimer's disease; Benfotiamine; Glycogen synthase kinase 3; High glucose

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BENFOTIAMINE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA;

ARTICLE; CELL STRAIN HEK293; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; MUTANT; PROTEIN EXPRESSION; SUPERNATANT; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; CELL SURVIVAL; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; THIAMINE;

EID: 84871448793     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-012-1264-0     Document Type: Article

References (30)

1. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, TorranceMA, et al. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: J Neurosci Res 2008 86(15) 3265-3274
2. Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab 2006, 32(5 Pt 1): 403-414. (Pubitemid 44841847)
3. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004, 61(5): 661-666. (Pubitemid 38637681)
4. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu- Asia Aging Study. Diabetes 2002, 51(4): 1256-1262. (Pubitemid 34438377)
5. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 2011, 15(9): 1807-1821.
6. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology. Biochem Soc Trans 2005, 33(Pt 5): 1041-1044. (Pubitemid 41659109)
7. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem 2009, 111(1): 242-249.
8. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008, 1147: 180-195.
9. Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007, 56(2): 384-402. (Pubitemid 350166529)
10. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2006, 9(3 Suppl): 309-317. (Pubitemid 44253325)
11. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007, 27(8): 1981-1991.
12. Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 2010, 133(Pt 5): 1342-1351.
13. Steinhilb ML, Turner RS, Gaut JR. ELISA analysis of betasecretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways. J Neurochem 2002, 80(6): 1019-1028. (Pubitemid 34809954)
14. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53(2): 474-481. (Pubitemid 38174565)
15. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63(7): 1187-1192. (Pubitemid 39350015)
16. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP. The effects of type 1 diabetes on cognitive performance: a metaanalysis. Diabetes Care 2005, 28(3): 726-735. (Pubitemid 40315341)
17. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999, 16(2): 93-112.
18. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 2004, 26(8): 1044-1080. (Pubitemid 39577337)
19. Lovestone S. Diabetes and dementia: is the brain another site of end-organ damage. Neurology 1999, 53(9): 1907-1909.
20. Avila J, Hernandez F. GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother 2007, 7(11): 1527-1533. (Pubitemid 350106832)
21. Geert JB, Salka S, Eric B, Carol B, Philip S. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006, 5: 64-74.
22. Gadau S, Emanueli C, Van LS, Graiani G, Todaro M, Meloni M, et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006, 49(2): 405-420. (Pubitemid 43185412)
23. Marchetti V, Menghini R, Rizza S, Vivanti A, Feccia T, Lauro D, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006, 55(8): 2231-2237. (Pubitemid 44743619)
24. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 2009, 4(11): e7917.
25. Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A, et al. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 2002, 16(13): 1738- 1748. (Pubitemid 35340354)
26. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol 2010, 223: 422-431.
27. Balakumar P, Chakkarwar VA, Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem 2009, 320: 149-162.
28. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 2006, 11(4): 294-329. (Pubitemid 46037130)
29. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000, (7): 793-803.
30. Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003, (52): 588-595. (Pubitemid 36323563)